Background: Current treatment regimens for pulmonary tuberculosis require at least 6 months of therapy. Immune adjuvant therapy with recombinant interferon-c1b (rIFN-cb) may reduce pulmonary inflammation and reduce the period of infectivity by promoting earlier sputum clearance.
Introduction
Mycobacterium tuberculosis (Mtb) infects one-third of the world's population, resulting in 9.2 million active cases per year [1] . Since the Directly Observed Therapy (Isoniazid, Rifampin, Pyrazinamide, Ethambutol 6 month Short Course, DOTS) approach is highly successful, the World Health Organization has set the goal of achieving 85% adherence, and the Global Plan to Stop TB has a vision of halving the prevalence and mortality of tuberculosis by 2015 [2] . Transgenic knockout models of mycobacteria-exposed mice demonstrate that interferon-c and its signaling intermediates are critical to host defense [3, 4] . In humans, mutational defects in the interferon-c receptor, the cytokine IL-12, or antibodies to interferon-c result in disseminated mycobacterial infection [5, 6] .
Sputum culture positive at two months, cavitation on chest radiography, being underweight, and bilateral pulmonary involvement increases the risk of treatment failure and/or relapse [7] . Responses of whole blood PBMC to PPD and other mycobacterial antigens are reduced in active tuberculosis probably due to suppressor T cells (Tregs ) or cytokines, e.g. IL-10 or TGF-b [8, 9] . Bronchoalveolar lavage (BAL) of patients with pulmonary tuberculosis has shown increases in inflammatory cytokines and percent CD4+ cells compared to uninfected controls, and in advanced, cavitary tuberculosis markers of effective immunity are reduced. Nitric oxide (NO) has been identified as a mechanism of mycobacterial killing, while mycobacteria can also be eliminated by autophagy, apoptosis, cytotoxic CD8+ cells, alpha defensins from neutrophils, and phagosomal-lysosomal rupture with subsequent cytosolic demise [10, 11, 12] . However, mycobacteria have evolved virulence factors to persist in macrophages, possibly disrupting the interferon-c signaling pathways. We hypothesized that pharmacologic doses of rIFN-c1b could augment the host immune response in TB, and to evaluate this we conducted a 4-month randomized, controlled clinical trial with rIFN-c1b at 200 mg/day for three days/week with three arms: nebulized rIFNc1b or subcutaneous rIFN-c1b with DOTS versus DOTS alone. End points were:: BAL cytokine release, treatment failure, sputum smear and culture conversion, and respiratory and systemic symptoms. We evaluated BAL cytokines,, mycobacterial and clinical response, immunological outcomes, and postulate mechanisms that rIFN-c1b augmented to achieve an improved outcome.
Methods
The protocol for this trial and supporting CONSORT checklist are available as supporting information; see Checklist S1 and Protocol S1.
Study Subjects
Patients with pulmonary tuberculosis were recruited from April 2005 to December 2006 in the Division of Pulmonology at the University of Cape Town with the following inclusion criteria: sputum smear and culture positive for Mycobacterium tuberculosis, and bilateral cavitary tuberculosis. We randomized 96 patients who met the entrance criteria. Four of these individuals grew Mtb (BACTEC method) resistant to both isoniazid and rifampin and were thus ineligible due to MDR-TB, two patients had negative cultures for Mtb, and one patient had received a streptomycin-containing regimen. They had been randomized with 4 subjects in the DOTS plus subcutaneous IFN-c, 2 in the DOTS alone group, and 1 in the DOTS plus nebulized IFN-c group. All of the remaining 89 patients had Mtb cultured from their sputum and were drug-sensitive. Respiratory symptoms (cough, wheeze, dyspnea grade 2 or 3, sputum volume ,10 ml) and night sweats (number/week) were reviewed at baseline and weekly during treatment by a blinded interviewer; oral temperature (fever defined as 38.5 uC) was recorded by the study nurse 3 times/week. IRB approval was obtained at NYU School of Medicine and the University of Cape Town; all study subjects signed informed consent in their native language. rIFN-c1b (recombinant, InterMune Brisbane, CA) was nebulized with an AeroEclipse breathactivated nebulizer (which improves alveolar deposition), or was administered subcutaneously at 200 micrograms (excipient normal saline) three times per week over 4 months. All patients had weekly sputum smear and culture to 4 months and were followed up at 12 months with sputum smear and culture.
Bronchoalveolar lavage
Bronchoalveolar lavage was performed at baseline and 4 months. Briefly, after local anesthesia with lidocaine, the bronchoscope was inserted via the nasal passage to the lower respiratory tract, wedged, and a 300-ml lavage was performed using 5, 20-ml aliquots of normal saline in each of three involved lung segments. The recovered fluid was pooled and filtered over sterile gauze, and a total cell count performed. A cytospin slide was stained with Diff-Quik and 500 cells counted to determine the cell differential. BAL supernatants were collected in RPMI over 24 hours at 10 6 BAL cells/ml. Cytokines IL-1b, IL-6, IL-8, TNF-a, and IL-10 were measured by Luminex Beadlyte ELISA assay. Immunoblots for C/ EBPb were done as previously described [13, 14, 15] .
Systemic Response
Peripheral blood was obtained between 3-5 weeks for in vitro stimulation. Mononuclear cells (PBMC) isolated by Ficoll-Paque were cultured for 5 days in the absence or presence of staphylococcal enterotoxin B, Mumps antigen, or PPD and pulsed with BrDU during the last 24 hr. Cells were labeled with PerCPCy5.5-anti-CD4 and allophycocyanin-anti-CD25, fixed and permeabilized, then labeled with FITC-anti-BrDU in the presence of DNase I. Labeled cells were analyzed on a FACSCalibur, and lymphoblasts displaying PerCP-Cy5.5 were identified as CD4+. Proliferating cells were detected as CD25+BrDU+ lymphoblasts.
The proliferation index is given by the %CD25+BrDU+lympho-blasts normalized by the %lymphoblast-sized cells in the CD4+ population in each culture.
Radiographic Studies
Prior to entry into the study, tuberculosis patients had to have a posterior-anterior and lateral chest x-ray to evaluate for the presence of cavities. At randomization and 4 months, each participant had a chest CT-scan at the Groote Schuur Hospital using a Somatom Balance apparatus (Siemens Medical, Ehrlangen, Germany) and a single breathhold technique. The collimator was set at 3 mm standard cuts from the superior margin of the clavicles to the adrenal glands. The standard reconstruction algorithm was used for soft tissue and high frequency filter for the lung. The internal volume of each cavity was assessed using internal cross-sectional diameters.
Statistical Analysis
The analysis, which included all 89 randomized and eligible subjects, was performed according to the intention-to-treat principle. Summary statistics (mean, median, standard deviation, and frequency distribution) were generated for baseline demographics and clinical presentations to characterize the study population. To compare the baseline characteristics between 3 treatment groups, one-way ANOVA or Kruskal-Wallis test was used for continuous variables, and Chi-square or Fisher's exact tests, for categorical variables ( Table 1 ). The primary endpoint of the study was the time to smear conversion and culture conversion. Kaplan Meier curves were generated for the time to smear conversion by treatment groups. The log-rank test was used to compare the Kaplan Meier curves before 4 weeks. The analysis of culture conversion was done in the same way. For the change of symptom at 4 weeks, we averaged the results from the 3rd, 4th and 5th week data for each subject, and used one-way ANOVA and two sample t-test for 3 group and two group comparisons, respectively. For the analysis of cell differentials in BAL, functional assays, and cavity sizes, the paired t-test or Wilcoxon signed rank test was used to evaluate the change from baseline to 16 weeks within each treatment group (Table 2) , and oneway ANOVA or Kruskal-Wallis test was used to compare the change from baseline to 16 weeks between treatment groups, as appropriate (Table 3) . No adjustment for multiple comparisons was used and no missing data were imputed. All tests were two sided and p-values less than 5% were considered statistically significant. All analyses were conducted using SAS software.
Results

Demographics
There were 96 patients who were randomized and 89 who were eligible for the study. 10 patients did not complete the trial including 4 patients who were lost to follow-up, 2 who withdrew consent, and 4 who were withdrawn due to serious adverse events (SAE's): 2 hepatitis, 1 community acquired pneumonia, 1 hypoxia. Also 1 died from massive hemoptysis, and 1 died in a domestic accident (the SAE occurred after 16 weeks but before the end of their DOTS so were left in the analysis, Figure 1 ). The SAE's were not thought to be treatment-related based on Data Safety Management Board review although the hypoxia in the patient with emphysema occurred during the bronchoscopy and the procedure was terminated.
The mean age of the tuberculosis patients who were eligible for the study ranged from 32-35 years and did not differ among groups (Table 1 ). The 3 groups were closely matched for gender (63% to 81% male), and race (56-63% mixed) and symptoms. Eighty percent had a history of smoking. There were 6 patients who were coinfected with HIV-1 and their mean CD4+ was 253 cells/mL (all with CD4+.200 and randomized to DOTS 2, DOTS plus subcutaneous 1 and nebulized 3. At baseline, the three groups were comparable in respiratory and constitutional symptoms (Table 1) .
Bronchoalveolar lavage
There was a significant increase in median percent lymphocytes from baseline to 16 weeks in two of three groups in BAL (Table 2 ; DOTS 4% to 15%; rIFN-c1b-SC 6% to 22%; rIFN-c1b-NEB 5% to 15%, p,0.01 for DOTS and rIFN-c1b-SC). There was no change in lymphocytes/ml BALF recovered. There was a significant decrease in median percent neutrophils from baseline to 16 weeks in all three groups in BAL (Table 2 ; DOTS 28% to 11%; rIFN-c1b-SC 30% to 2%; rIFN-c1b-NEB 24% to 4%), and a remarkable decline in neutrophils/ml BALF recovered in all 3 groups (DOTS 3.98 to 0.30610 4 ; rIFN-c1b-SC 3.59 to 0.23610 4 ; rIFN-c1b-NEB 2.10 to 0.26610 4 ). The percentage of macrophages increased slightly over the 16 weeks in all 3 groups. However, the macrophages/ml decreased 2-fold in all three groups (Table 2 ).
Functional Assays
There was a significant decline in inflammatory cytokines in 24 hour BAL supernatants in the nebulized rIFN-c1b group only Peripheral blood lymphocytes showed a significant 2.8-fold increase in Th1 proliferation when stimulated with PPD but not SEB or MUMPS in vitro ( Figure 3 and Table 3 ), demonstrating an enhanced antigen-specific systemic response after one month of both nebulized and subcutaneous rIFN-c1b administration.
Chest radiology
There was a striking improvement in cavity size as assessed by HRCT in all 3 groups between baseline and 16 weeks; however, the rIFN-c1b groups did not differ from DOTS alone (Cavity in mm: DOTS 34+/211 to 20+/216; rIFN-c1b-SC 39+/224 to 29+/224; rIFN-c1b-NEB 34+/213 to 18+/217.
Sputum Smear Conversion and Change in Symptoms
At 4 weeks, there was a significantly higher smear conversion rate in the nebulized rIFN-c1b group compared to the DOTS control and subcutaneous rIFN-c1b plus DOTS groups (60% versus 36% at 4 weeks, p = 0.03 for comparing Kaplan-Meier curves before 4 weeks, Figure 4A) . A higher culture conversion rate at 4 weeks was also observed in the nebulized group compared to DOTS control and subcutaneous rIFN-c1b plus DOTS (32% vs 18% at 4 weeks, p = 0.15). There was a significant reduction in fever in both rIFNc1b groups compared to control DOTS at 4 and 8 weeks ( Figure 4B ) and complaints of night sweats at 4 weeks in both rIFN-c1b groups compared to DOTS control. Also, there was a significant reduction in the proportion with wheeze in both IFN-c1b groups at 4, 8, and 12 weeks compared to DOTS control. In addition, at 12 weeks there was a significant reduction in cough in the groups receiving rIFN-c1b compared to DOTS control. There was no statistically significant difference between treatment arms in the incidence of tiredness, poor appetite, sputum volume, or dyspnea. There was one treatment failure at 12 months in the DOTS alone group.
Discussion
Immunoadjunctive therapy with nebulized rIFN-c1b plus DOTS significantly reduced lung inflammatory cytokines in BAL supernatants at the 16 week time point. We treated five multiple-drug resistant tuberculosis patients with nebulized rIFNc1b while continuing their failing second-line regimens at a dose of Figure 1 . Flow Diagram showing number of study subjects screened, randomized to the three study groups n = 96, and who met inclusion criteria, n = 89). 10 patients did not complete the trial including 4 patients who were lost to follow-up, 2 who withdrew consent, and 4 who were withdrawn due to serious adverse events (SAE's): 2 hepatitis, 1 community acquired pneumonia, 1 hypoxia, 1 who died from massive hemoptysis, and 1 died in a domestic accident two weeks before the end of the trial (the last two occurred after 16 weeks but before the end of their DOTS so were left in the analysis). doi:10.1371/journal.pone.0006984.g001 Proliferation indices (mean6SEM) were determined by flow cytometry (Fig. 3) following in vitro stimulation for 5 days with a T cell mitogen (SEB), Mumps antigen, or PPD at pretitered concentrations. Values given are those determined in the presence of antigen less that determined in the absence of antigen for the same specimen. The proliferation index in the absence of antigen was 0.260.4 for all specimens (N = 54). Significance p was determined using unpaired t tests at 95% confidence interval. doi:10.1371/journal.pone.0006984.t003 500 mg three times weekly for four weeks [13] . In all five patients, the sputum converted to negative, and symptoms improved. In order to investigate the mechanisms of these responses, we used nebulized rIFN-c1b in eleven drug-sensitive tuberculosis patients, and found an increase in signaling molecules STAT-1, IRF-1 and IRF-9 [14] . In addition, nebulized rIFN-c1b induced IP-10 downstream from these signaling molecules, but not inducible nitric oxide synthase (iNOS) [15] . There was a recruitment of lymphocytes and reduction in the neutrophil inflammation in the lung in all three groups, which manifested clinically as a dramatic resolution of the macrophage-neutrophilic alveolitis in the lower respiratory tract. Concomitantly with the increase in BAL lymphocytes, blood CD4+ cells doubled in their proliferative capacity to PPD or Mtb culture filtrate protein stimulation (data not shown) at the 4 week time point in both immunoadjunctive rIFN-c1b groups of drug-sensitive pulmonary tuberculosis.
Immunoadjunctive therapy cleared M tuberculosis from the sputum and resolved the classic symptoms of fever, night sweats, wheeze, cough and malaise more rapidly than treatment with either DOTS or DOTS plus subcutaneous rIFN-c1b. This finding suggests that nebulized rIFN-c1b could reduce transmission due to more rapid clearance of M tuberculosis during the first 4 weeks. The subcutaneous rIFN-c1b plus DOTS was not different from control since only nebulized rIFN-c reaches the lower respiratory tract in pharmacological amounts to have a biological effect. All treatment groups experienced radiographic improvement with resolution of cavities by 16 weeks. Limitations of the study include the fact that this was an open-label, unblinded study without a placebo, and there was no group with rIFN-c1b alone.
At 12 months there was only one study subject who had a treatment failure with culture positive sputum, and this occurred in the DOTS only control arm. TB Trials Consortium Study 22 comparing rifapentene and isoniazid once a week versus rifampicin and isoniazid twice a week reported bilateral pulmonary involvement and cavitation on chest radiograph were two risk factors (out of five) for treatment failure/relapse that occurred in 74/1004 (14.9%) of the TB patients [7] . Although our numbers were much smaller, we had no treatment failures/relapses among the adjunctive rIFN-c1b groups. This is the first major report on the efficacy of rIFN-c1b in a randomized clinical trial. In the first study of nebulized versus subcutaneous rIFN-c in humans, IP-10 mRNA was detected in BAL cells only in the nebulized patients and not subcutaneous rIFNc treated subjects [16] . This probably explains our finding that only nebulized rIFN-c1b and not subcutaneous rIFN-c1b was successful in clearing the sputum of Mtb and reducing the spontaneous release of inflammatory cytokines in 24 hour BAL supernatants. A pilot study of intramuscular rIFN-c plus second-line anti-TB drugs over a 6-month period in 8 MDR-TB patients from Cuba showed sputum conversion over 1-3 months and marked improvement of radiographic abnormalities [17] . Giosue and colleagues nebulized IFN-a, a type I interferon, for 2 months as an adjunct in a randomized controlled clinical trial in 20 drug sensitive tuberculosis patients [18] . Improvements in Mtb number in the sputum at 7 days, reduced fever by 7 days, reduced number of nodules and area of consolidation on CT-scans at 2 months, and significant decreases in BAL fluid amounts at 2 months of IL-1b, IL-6, and TNF-a were noted in the IFN-a group [18] . In a clinical trial of interleukin-2 adjunctive therapy performed in Uganda, 110 TB patients were randomized to IL-2 subcutaneously twice/day for the first 30 days in addition to DOTS versus DOTS alone. Seventeen percent versus 30% sputum conversion, respectively, was observed at 4 weeks [19] . Tramontana and colleagues conducted a clinical trial of thalidomide in TB patients blocking TNF-a leading to enhanced weight gain and increased serum IFN-c in vivo [20] . Microarray analyses of BAL cells from TB patients shows elevated cytokine IL-1b, adhesion molecule ICAM, TGF-b, apoptosis genes, and IFN-c pathway genes [21] . Immunohistochemistry of Mtb-laden lungs show increased IFN-c, IL-12, IP-10, and TGF-b in granulomas and areas with pneumonitis with reductions in IL-10 and IL-4 compared to controls [22] . BAL in Brazilian TB patients shows increased mRNA for TGF-bRI and II and IL-10 with increased protein for IFN-c, IL-10, and bioactive TGF-b suggesting that TB has both stimulatory and counterregulatory molecules that may ultimately down-regulate the Th1 response [23] . Th2 cytokines may be inhibited by antagonists such as IL-4d2 that may be increased in TB [24] . PBMC responses from TB patients to Mtb in vitro are reduced, probably due to IL-10 which was increased in BAL cell supernatants. Gold and colleagues have reported low levels of Surfactant Protein A in BAL from involved segments of active TB along with increased IL-6, and reduced inhibitory C/EBPb [25] .
We noted that BAL lymphocytes increased in all three groups after 4 months of therapy. Mtb is suppressive of the T cell immune response, e.g. IFN-c response to PPD-stimulated PBMC is depressed and TGF-b and IL-10 are increased at the beginning of TB treatment and return to normal levels only at the end of treatment 6-9 months later [26, 27] . In Gambian TB patients, T cell response to PPD from blood or pleural fluid was impaired pretreatment, that changed to IFN-c release after successful treatment or IL-4 after treatment failure; addition of IFN-a or IL-12 in vitro pre-treatment could alter the response to Th1 suggesting that immunotherapy could increase host defense against mycobacteria [28] . We showed significantly increased PBMC proliferative capacity to PPD in the nebulized and subcutaneous rIFN-c1b groups within 3-5 weeks of immunoadjunctive therapy.
Inflammatory cytokines IL-1b, IL-6, IL-8, IFN-c and TNF-a as well as anti-inflammatory cytokines IL-10 and TGF-b (and its TGF-bRI and RII) are elevated in BAL from active TB patients [29] . The inflammatory response in the lung in TB may include an increase in neutrophils, particularly in radiographically abnormal areas. Zhang and colleagues have previously reported that Mtb and its cell wall components stimulated IL-8 protein release and mRNA expression in vitro from alveolar macrophages [30] . In summary, the addition of nebulized recombinant interferon-c1b to DOTS in a randomized, controlled clinical trial resulted in reduced BAL cytokines, more rapid clearance of Mtb from the sputum, improved symptoms, and reduced inflammatory macrophage-neutrophil alveolitis. These findings suggest that nebulized recombinant interferon-c1b may have a role in adjunctive immune stimulation in patients with cavitary tuberculosis.
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